Ewing Sarcoma Drug Therapy: Current Standard of Care and Emerging Agents

Area of Science:

• Oncology
• Molecular Biology
• Clinical Trials

Background:

• Ewing sarcoma is a rare bone and soft tissue cancer.
• It is characterized by specific genetic translocations, notably EWSR1::FLI1.
• Current treatments rely on non-selective chemotherapy due to challenges in targeting the oncogenic driver.

Purpose of the Study:

• To review recent clinical trials in Ewing sarcoma treatment over the past decade.
• To highlight established and investigational drug therapies.
• To provide an overview of current management strategies for localized, metastatic, and recurrent disease.

Main Methods:

• Review of clinical trials published in the last 10 years.
• Analysis of evidence for contemporary drug therapies.
• Examination of novel therapies in clinical investigation.

Main Results:

• Interval-compressed chemotherapy is now an international standard for newly diagnosed localized Ewing sarcoma.
• High-dose chemotherapy and IGF-1R inhibition did not demonstrate significant benefit in newly diagnosed metastatic disease.
• Current approaches for recurrent Ewing sarcoma involve specific chemotherapy regimens and targeted therapies.

Conclusions:

• Treatment strategies for Ewing sarcoma are advancing, with established standards for localized disease.
• Further research is needed to improve outcomes for metastatic and recurrent Ewing sarcoma.
• Novel therapeutic approaches are under active investigation to address unmet needs in Ewing sarcoma management.